Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report

A diagnosis of idiopathic hypereosinophilic syndrome was made in a 68-year-old woman in 2002. A diagnostic work-up including radiological evaluation failed to reveal an overt lymphoproliferative disorder. Currently, 6 months after the revised diagnosis, the patient is well with an eosinophil count of 0.3 · 109/l on alemtuzumab (30 mg) every 3 weeks.